Skip to main content
Asher A Chanan-Khan on Muck Rack

Asher A Chanan-Khan

As seen in: Nature, Medscape, The Lancet, HMP Global Learning Network, Blood, Future Medicine, ONCOLOGY journal, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Asher A

Contact Asher A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia

|
By Ricardo D. Parrondo, Sikander Ailawadhi, Ashley Zimmerman, Vivek Roy, Aneel Paulus, Asher A Chanan-Khan, Betsy R. Knopf, Carly J. Kasik, Dustin Chapin, Keisha Heslop
| Nature Verified
Dear Editor, Due to the advent of novel targeted therapies such as BTK inhibitors and BCL-2 inhibitors, the survival outcomes of patients with chronic lymphocytic leukemia (CLL) have improved considerably over the last decade [1,2,3,4]. In the RESONATE 2 trial, single agent ibrutinib resulted in a 9-year progression free survival (PFS) rate of 50% [4].
Open in Who Shared Issue with article?

Emerging Therapies Transform Waldenström Macroglobulinemia

|
By Asher A Chanan-Khan
| Oncology Learning Network Verified
Skip to main content Videos At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Asher Chanan-Khan, MD, Mayo Clinic, Jacksonville, Florida, discusses recent advances in Waldenström’s macroglobulinemia including developments in BTK inhibitors, BCL2 combinations, and novel targeted therapies. Dr Chanan-Khan emphasizes the expanding role of immunotherapy and targeted approaches that are delivering high response rates and durable remissions, even in heavily pretreated patients.
Open in Who Shared Issue with article?

Key Data on Hypertension and Atrial Fibrillation in Patients With CLL

|
By Ricardo D. Parrondo, Asher A Chanan-Khan, Pooja advani
| ONCOLOGY journal Verified
November 17, 2023 Ricardo Parrondo, MD, discusses that in treating chronic lymphocytic leukemia, BTK inhibitors like ibrutinib can pose cardiovascular risks, including hypertension; he suggests that in choosing a BTK inhibitor one should consider the patient's preexisting cardiovascular conditions. Asher A.
Open in Who Shared Issue with article?
See all 20 licensed articles (23 Total)